Department of Immunology and Cell Biology, Institute of Parasitology and Biomedicine Lopez-Neyra, CSIC, Granada, Spain.
Circ Res. 2013 May 24;112(11):1444-55. doi: 10.1161/CIRCRESAHA.112.300695. Epub 2013 Apr 17.
Proliferation and migration of smooth muscle cells (SMCs) are key steps for the progression of atherosclerosis and restenosis. Cortistatin is a multifunctional neuropeptide belonging to the somatostatin family that exerts unique functions in the nervous and immune systems. Cortistatin is elevated in plasma of patients experiencing coronary heart disease and attenuates vascular calcification.
To investigate the occurrence of vascular cortistatin and its effects on the proliferation and migration of SMCs in vitro and in vivo and to delimitate the receptors and signal transduction pathways governing its actions.
SMCs from mouse carotid and human aortic arteries and from human atherosclerotic plaques highly expressed cortistatin. Cortistatin expression positively correlated with the progression of arterial intima hyperplasia. Cortistatin inhibited platelet-derived growth factor-stimulated proliferation of human aortic SMCs via binding to somatostatin receptors (sst2 and sst5) and ghrelin receptor, induction of cAMP and p38-mitogen-activated protein kinase, and inhibition of Akt activity. Moreover, cortistatin impaired lamellipodia formation and migration of human aortic SMCs toward platelet-derived growth factor by inhibiting, in a ghrelin-receptor-dependent manner, Rac1 activation and cytosolic calcium increases. These effects on SMC proliferation and migration correlated with an inhibitory action of cortistatin on the neointimal formation in 2 models of carotid arterial ligation. Endogenous cortistatin seems to play a critical role in regulating SMC function because cortistatin-deficient mice developed higher neointimal hyperplasic lesions than wild-type mice.
Cortistatin emerges as a natural endogenous regulator of SMCs under pathological conditions and an attractive candidate for the pharmacological management of vascular diseases that course with neointimal lesion formation.
平滑肌细胞(SMC)的增殖和迁移是动脉粥样硬化和再狭窄进展的关键步骤。皮质抑素是一种多功能神经肽,属于生长抑素家族,在神经系统和免疫系统中发挥独特的功能。皮质抑素在经历冠心病的患者的血浆中升高,并减轻血管钙化。
研究血管皮质抑素的发生及其对体外和体内 SMC 增殖和迁移的影响,并划定其作用的受体和信号转导途径。
来自小鼠颈动脉和人主动脉以及人动脉粥样硬化斑块的 SMC 高度表达皮质抑素。皮质抑素的表达与动脉内膜增生的进展呈正相关。皮质抑素通过与生长抑素受体(sst2 和 sst5)和 ghrelin 受体结合、诱导 cAMP 和 p38-有丝分裂原激活蛋白激酶、抑制 Akt 活性,抑制血小板衍生生长因子刺激的人主动脉 SMC 增殖。此外,皮质抑素通过以 ghrelin 受体依赖性方式抑制 Rac1 激活和细胞溶质钙增加,损害人主动脉 SMC 向血小板衍生生长因子的片状伪足形成和迁移。SMC 增殖和迁移的这些影响与皮质抑素在 2 种颈动脉结扎模型中的抑制新生内膜形成的作用相关。内源性皮质抑素似乎在调节 SMC 功能中起关键作用,因为皮质抑素缺陷型小鼠比野生型小鼠发展出更高的新生内膜增生病变。
皮质抑素作为一种在病理条件下调节 SMC 的天然内源性调节剂出现,是治疗伴有新生内膜形成的血管疾病的有吸引力的候选药物。